Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP10744028.1Aexternal-prioritypatent/EP2398780B1/en
Application filed by Astrazeneca AbfiledCriticalAstrazeneca Ab
Publication of CY1114176T1publicationCriticalpatent/CY1114176T1/en
Acyclic And Carbocyclic Compounds In Medicinal Compositions
(AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
Εδώ περιγράφεται τουλάχιστον ένα παράγωγο κυκλοπροπυλαμιδίου, τουλάχιστον μια φαρμακευτική σύνθεση που περιλαμβάνει τουλάχιστον ένα παράγωγο κυκλοπροπυλαμιδίου που περιγράφεται εδώ, και τουλάχιστον μία μέθοδος χρήσης τουλάχιστον ενός παραγώγου κυκλοπροπυλαμιδίου που περιγράφεται εδώ για την αντιμετώπιση με αυτό τουλάχιστον μιας κατάστασης που σχετίζεται με τον υποδοχέα Η3 της ισταμίνης.Herein is described at least one cyclopropylamide derivative, at least one pharmaceutical composition comprising at least one cyclopropylamide derivative described herein, and at least one method of using at least one cyclopropylamide derivative described herein for treating at least one condition related to the histamine H3 receptor.
CY20131100520T2009-02-202013-06-27
CYCLOPROPYLAMIDE PRODUCTS TARGETING TO THE H3 receptor of histamine
CY1114176T1
(en)
ANILINA-PYRIMIDINE DERIVATIVES SUBSTITUTED WITH SULFOXIMINE AS INHIBITORS OF CYCLINE-DEPENDENT KINASE (CDK), PRODUCTION AND USE OF THE SAME AS MEDICINAL PRODUCTS